Back to Search
Start Over
An anti-aging drug today: from senescence-promoting genes to anti-aging pill.
- Source :
-
Drug discovery today [Drug Discov Today] 2007 Mar; Vol. 12 (5-6), pp. 218-24. Date of Electronic Publication: 2007 Feb 09. - Publication Year :
- 2007
-
Abstract
- Numerous mutations increase lifespan in diverse organisms from worms to mammals. Most genes that affect longevity encode components of the target of rapamycin (TOR) pathway, thus revealing potential targets for pharmacological intervention. I propose that one target, TOR itself, stands out, simply because its inhibitor (rapamycin) is a non-toxic, well-tolerated drug that is suitable for everyday oral administration. Preclinical and clinical data indicate that rapamycin is a promising drug for age-related diseases and seems to have anti-tumor, bone-sparing and calorie-restriction-mimicking 'side-effects'. I also discuss other potential anti-aging agents (calorie restriction, metformin, resveratrol and sirtuins) and their targets, interference with the TOR pathway and combination with antioxidants.
- Subjects :
- Aging genetics
Aging physiology
Animals
Antioxidants pharmacology
Caloric Restriction
Cell Cycle Proteins drug effects
Cellular Senescence drug effects
Enzyme Inhibitors pharmacology
Humans
Immunosuppressive Agents adverse effects
Longevity drug effects
Longevity genetics
Metformin pharmacology
Phosphatidylinositol 3-Kinases drug effects
Phosphotransferases (Alcohol Group Acceptor) drug effects
Resveratrol
Saccharomyces cerevisiae Proteins drug effects
Sirolimus adverse effects
Sirtuins pharmacology
Stilbenes pharmacology
Aging drug effects
Drug Delivery Systems
Immunosuppressive Agents pharmacology
Sirolimus pharmacology
Subjects
Details
- Language :
- English
- ISSN :
- 1359-6446
- Volume :
- 12
- Issue :
- 5-6
- Database :
- MEDLINE
- Journal :
- Drug discovery today
- Publication Type :
- Academic Journal
- Accession number :
- 17331886
- Full Text :
- https://doi.org/10.1016/j.drudis.2007.01.004